On June 12, 2009, Genaera Corporation transferred all of its assets and liabilities to the Genaera Liquidating Trust in accordance with the Plan of Complete Liquidation and Dissolution adopted at a Special Meeting of Stockholders on June 4, 2009. Details of the Plan of Dissolution as described in the proxy for the Special Meeting and a copy of the Liquidating Trust may be found in the Company filings section of the SEC website at www.sec.gov.

Creditors, vendors and other persons having business with Genaera Corporation should contact the Trustee at trustee@genaera.com.

Alternatively they may leave a voice mail at 610-941-4015 or send faxes 610-941-5399.

Click here to view The Genaera Liquidating Trust FAQ's

• Trodusquemine (MSI-1436)
• MEDI-528 (Anti-IL-9)

• MSI-1436, the core internal asset of Genaera, is a clinical candidate in Phase 1 development for the treatment of type 2 diabetes and obesity. Genaera initiated its first-in-man clinical studies in 2Q07.
• MEDI-528 the second core asset out-licensed to Astra Zeneca/MedImmune is being evaluated in Phase 2 clinical studies with applicability in the treatment of asthma. Please refer to www.medimmune.com for status of this program.